SGLT2 Inhibitor TrEatment iN Patients Awaiting cOronary arTery bYpass Surgery to Reduce Post-opErative AF

PHASE3RecruitingINTERVENTIONAL
Enrollment

800

Participants

Timeline

Start Date

April 4, 2024

Primary Completion Date

December 4, 2027

Study Completion Date

December 4, 2028

Conditions
Chronic Coronary SyndromeAtrial Fibrillation
Interventions
DRUG

Dapagliflozin 10mg Tab

Dapagliflozin once daily for a minimum of seven days while awaiting scheduled CABG and up until discharge with a short interruption for surgery.

DRUG

Placebo Tab

Matching placebo once daily for a minimum of seven days while awaiting scheduled CABG and up until discharge with a short interruption for surgery.

Trial Locations (8)

70185

RECRUITING

Department of cardiology, Örebro

Unknown

NOT_YET_RECRUITING

St. Anne University Hospital, Brno

RECRUITING

Department of Cardiothoracic and Vascular Surgery, Aarhus University Hospital, Aarhus, Denmark, Aarhus

NOT_YET_RECRUITING

Department of Cardiothoracic Surgery, Kobenhavn, Copenhagen

NOT_YET_RECRUITING

Odense University Hospital, Odense

RECRUITING

Sahlgrenska University Hospital, Gothenburg

NOT_YET_RECRUITING

Linköping University Hospital, Linköping

RECRUITING

Skane University Hospital, Lund

All Listed Sponsors
collaborator

Odense University Hospital

OTHER

collaborator

Aarhus University Hospital

OTHER

collaborator

Örebro University, Sweden

OTHER

collaborator

Sahlgrenska University Hospital

OTHER

collaborator

Göteborg University

OTHER

collaborator

University of Leeds

OTHER

collaborator

Skane University Hospital

OTHER

collaborator

London School of Hygiene and Tropical Medicine

OTHER

collaborator

St. Anne's University Hospital Brno, Czech Republic

OTHER

collaborator

Mount Sinai Hospital, New York

OTHER

collaborator

Icahn School of Medicine at Mount Sinai

OTHER

collaborator

University Hospital, Linkoeping

OTHER

collaborator

Rigshospitalet, Denmark

OTHER

lead

Region Örebro County

OTHER